Compare US Global Jets ETF (JETS) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs Tango Therapeutics Inc. — how do they compare? US Global Jets ETF trades at $25.96 (market cap $766.85M), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is far larger — about 4.9× US Global Jets ETF's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, US Global Jets ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 27 Days and Tango Therapeutics Inc. for 0 Days on average.
| JETS | TNGX | |
|---|---|---|
Market Cap | $766.85M | $3.74B |
Volume | 3,093,704 | 3,438,781 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $32.90 |
52-Week Low | $23.64 | $7.50 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | — | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS (U.S. Global Jets ETF) trades at $26.80, down 0.81% amid bearish technical signals with 17 sell indicators versus 5 buy signals. The ETF faces headwinds from rising fuel costs and geopolitical tensions, though oversold RSI levels suggest potential near-term support. Recent news highlights competitive pressure from defense-focused aerospace ETFs that have outperformed JETS on total returns.
Outlook remains cautious given fuel price volatility and airline earnings uncertainty. Investment opportunity exists for contrarians betting on travel recovery, but risks include sustained high oil prices and weaker-than-expected demand. The ETF's focus on pure-play airlines increases sensitivity to operational cost pressures compared to diversified aerospace funds.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
